Related Experiment Video
Updated: Feb 19, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Production and Evaluation of Specific Single-Chain Antibodies against CTLA-4 for Cancer-Targeted Therapy
Farideh Hosseinzadeh1,2, Saeed Mohammadi1,2, Foroogh Nejatollahi1,2
1Shiraz HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Background:
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) molecules are expressed on T-cells and inhibit their function by inhibiting activation of subsequent T-cell molecular pathways. Blocking of CTLA-4 inhibits the growth of malignant tumor cells. Anti-CTLA-4 monoclonal antibodies activate the immune system against cancer. Due to several advantages of single-chain antibodies (scFvs) compared to monoclonal antibodies in cancer immunotherapy, specific anti-CTLA-4 scFvs (single-chain variable fragment) were selected in this study.
Methods:
A phage antibody display library of scFvs was analyzed and a panning process was performed against an immunodominant epitope of CTLA-4. PCR and DNA fingerprinting were used to differentiate the specific clones. The specificity of the selected clones was investigated by phage ELISA (Enzyme-linked immunosorbent assay).
Results:
Two specific clones with frequencies of 35 and 20% were identified. The clones reacted with the corresponding epitope on ELISA, while no reactivity was observed with an unrelated peptide, M13KO7 helper phage, unrelated scFvs, or no peptide as negative controls.
Conclusion:
Targeted therapy against cancer markers is an ideal treatment strategy. Specific human anti-CTLA-4scFvs were selected in this study. These scFvs bound the related epitope. These antibodies have the potential to be used for targeted therapy, where the blocking of CTLA4 receptor is needed. The study suggests further evaluation of the selected scFvs to reveal the effects of the selected antibodies.
Insights
Researchers selected specific human single-chain variable fragments (scFvs) targeting Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). These scFvs show potential for cancer immunotherapy by blocking CTLA-4 signaling pathways.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) negatively regulates T-cell activation, impacting anti-tumor immunity.
- Blocking CTLA-4 enhances the immune response against malignant tumors.
- Single-chain variable fragments (scFvs) offer advantages over monoclonal antibodies in cancer immunotherapy.
Purpose of the Study:
- To select specific human anti-CTLA-4 scFvs for potential cancer immunotherapy.
- To develop targeted therapies by blocking CTLA-4 receptor function.
Main Methods:
- Utilized a phage antibody display library and panning against a CTLA-4 epitope.
- Employed PCR and DNA fingerprinting for clone differentiation.
- Assessed clone specificity using phage ELISA.
Main Results:
- Identified two specific anti-CTLA-4 scFv clones with frequencies of 35% and 20%.
- Confirmed epitope binding via ELISA.
- Demonstrated high specificity, with no cross-reactivity to negative controls.
Conclusions:
- Selected human anti-CTLA-4 scFvs specifically bind their target epitope.
- These scFvs hold potential for targeted cancer therapy by inhibiting CTLA-4.
- Further evaluation is recommended to elucidate the therapeutic effects of these antibodies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy